. 2013 Feb 5;8(2):e56046. doi: 10.1371/journal.pone.0056046

Table 3. Parameters of contractile force measurements represented in Figure 3: sensitivity (pD₂) and maximal responses (E_max) to norepinephrine (NE), endothelin-1 (ET-1) and angiotensin II (AngII) in aorta and vena cava after in vitro incubation with vehicle or 100 nM febuxostat.

	Aorta		Vena cava
	Vehicle	Febuxostat	Vehicle	Febuxostat
NE pD₂ (−logEC₅₀, M)	7.19±0.05	7.26±0.04	6.41±0.04	6.53±0.05
NE E_max (% 10⁻⁵ M PE/NE contraction)	113.70±19.73	95.95±24.64	119.04±27.17	89.87±13.93
ET-1 pD₂ (−logEC₅₀, M)	8.20±0.08	8.20±0.09	8.56±0.05	8.51±0.04
ET-1 E_max (% 10⁻⁵ M PE/NE contraction)	120.33±7.18	130.70±17.66	382.68±28.95	424.20±43.64
AngII pD₂ (−logEC₅₀, M)	8.00±0.04	7.82±0.11	8.67±0.11	193.40±56.50
AngII E_max (% 10⁻⁵ M PE/NE contraction)	35.93±5.88	35.20±4.29	8.60±0.12	197.66±44.90

Data are expressed as means ± SEM for N = 6–8.

Table 3. Parameters of contractile force measurements represented in Figure 3: sensitivity (pD2) and maximal responses (Emax) to norepinephrine (NE), endothelin-1 (ET-1) and angiotensin II (AngII) in aorta and vena cava after in vitro incubation with vehicle or 100 nM febuxostat.